CAR-T Breakthrough Targets Brain Cancer, Dual-Target Therapy Clears Tumours Others Can't Reach

Narayana Health in Kolkata has documented a successful dual-target CAR T-cell therapy for primary central nervous system lymphoma—a notoriously hard-to-treat brain cancer—in a 62-year-old Myanmar patient who had failed four rounds of high-dose chemotherapy. This isn't incremental progress; it's proof that the next generation of engineered immune cells can hunt down solid brain tumours that previous CAR-T approaches missed, targeting what researchers call the "faint" molecular...